174 related articles for article (PubMed ID: 34638364)
1. Stroma AReactive Invasion Front Areas (SARIFA)-A New Easily to Determine Biomarker in Colon Cancer-Results of a Retrospective Study.
Martin B; Grosser B; Kempkens L; Miller S; Bauer S; Dhillon C; Banner BM; Brendel EM; Sipos É; Vlasenko D; Schenkirsch G; Schiele S; Müller G; Märkl B
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638364
[TBL] [Abstract][Full Text] [Related]
2. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes.
Grosser B; Glückstein MI; Dhillon C; Schiele S; Dintner S; VanSchoiack A; Kroeppler D; Martin B; Probst A; Vlasenko D; Schenkirsch G; Märkl B
J Pathol; 2022 Jan; 256(1):71-82. PubMed ID: 34580877
[TBL] [Abstract][Full Text] [Related]
3. Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion.
Reitsam NG; Grosser B; Enke JS; Mueller W; Westwood A; West NP; Quirke P; Märkl B; Grabsch HI
Transl Oncol; 2024 Jun; 44():101913. PubMed ID: 38593584
[TBL] [Abstract][Full Text] [Related]
4. Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor-adipocyte interaction indicating an altered immune response.
Grosser B; Heyer CM; Austgen J; Sipos E; Reitsam NG; Hauser A; VanSchoiack A; Kroeppler D; Vlasenko D; Probst A; Novotny A; Weichert W; Keller G; Schlesner M; Märkl B
Gastric Cancer; 2024 Jan; 27(1):72-85. PubMed ID: 37874427
[TBL] [Abstract][Full Text] [Related]
5. Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study.
Ulase D; Behrens HM; Röcken C
Virchows Arch; 2024 May; ():. PubMed ID: 38748262
[TBL] [Abstract][Full Text] [Related]
6. Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA).
Reitsam NG; Märkl B; Dintner S; Sipos E; Grochowski P; Grosser B; Sommer F; Eser S; Nerlinger P; Jordan F; Rank A; Löhr P; Waidhauser J
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765951
[TBL] [Abstract][Full Text] [Related]
7. Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
Grosser B; Emmerson J; Reitsam NG; Cunningham D; Nankivell M; Langley RE; Allum WH; Trepel M; Märkl B; Grabsch HI
Br J Cancer; 2024 Feb; 130(3):457-466. PubMed ID: 38123705
[TBL] [Abstract][Full Text] [Related]
8. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
Enke JS; Groß M; Grosser B; Sipos E; Steinestel J; Löhr P; Waidhauser J; Lapa C; Märkl B; Reitsam NG
BMC Cancer; 2024 Jan; 24(1):65. PubMed ID: 38216952
[TBL] [Abstract][Full Text] [Related]
9. Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biology.
Reitsam NG; Grozdanov V; Löffler CML; Muti HS; Grosser B; Kather JN; Märkl B
Cancer Gene Ther; 2024 Feb; 31(2):207-216. PubMed ID: 37990064
[TBL] [Abstract][Full Text] [Related]
10. Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study.
Hu Q; Wang Y; Yao S; Mao Y; Liu L; Li Z; Chen Y; Zhang S; Li Q; Zhao Y; Fan X; Cui Y; Zhao K; Liu Z
Cancer Res Commun; 2023 Jun; 3(6):1057-1066. PubMed ID: 37377615
[TBL] [Abstract][Full Text] [Related]
11. Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers.
Konishi T; Shimada Y; Lee LH; Cavalcanti MS; Hsu M; Smith JJ; Nash GM; Temple LK; Guillem JG; Paty PB; Garcia-Aguilar J; Vakiani E; Gonen M; Shia J; Weiser MR
Am J Surg Pathol; 2018 Jun; 42(6):705-714. PubMed ID: 29624511
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of extramural deposits and extracapsular lymph node invasion in colon cancer.
Al Sahaf O; Myers E; Jawad M; Browne TJ; Winter DC; Redmond HP
Dis Colon Rectum; 2011 Aug; 54(8):982-8. PubMed ID: 21730787
[TBL] [Abstract][Full Text] [Related]
13. Tumor proportion in colon cancer: results from a semiautomatic image analysis approach.
Martin B; Banner BM; Schäfer EM; Mayr P; Anthuber M; Schenkirsch G; Märkl B
Virchows Arch; 2020 Aug; 477(2):185-193. PubMed ID: 32076815
[TBL] [Abstract][Full Text] [Related]
14. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma.
Okuyama T; Oya M; Ishikawa H
Dis Colon Rectum; 2002 May; 45(5):628-34. PubMed ID: 12004212
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of classified extramural tumor deposits and extracapsular lymph node invasion in T3-4 colorectal cancer: a retrospective single-center study.
Yamano T; Semba S; Noda M; Yoshimura M; Kobayashi M; Hamanaka M; Beppu N; Yano A; Tsukamoto K; Matsubara N; Tomita N
BMC Cancer; 2015 Nov; 15():859. PubMed ID: 26545360
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Tumor-Budding Grade in Stages 1-3 Colon Cancer: A Retrospective Cohort Study.
Oh BY; Park YA; Huh JW; Yun SH; Kim HC; Chun HK; Kim SH; Ha SY; Lee WY; Cho YB
Ann Surg Oncol; 2018 Jan; 25(1):204-211. PubMed ID: 29086140
[TBL] [Abstract][Full Text] [Related]
17. Tumor budding as an indicator of isolated tumor cells in lymph nodes from patients with node-negative colorectal cancer.
Park SY; Choe G; Lee HS; Jung SY; Park JG; Kim WH
Dis Colon Rectum; 2005 Feb; 48(2):292-302. PubMed ID: 15616755
[TBL] [Abstract][Full Text] [Related]
18. Histomorphological Evaluation of Desmoplastic Tumor Stroma in Malignant Ovarian Surface Epithelial Tumors.
Ahuja S; Zaheer S; Ranga S
J Midlife Health; 2023; 14(2):107-111. PubMed ID: 38029034
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
[TBL] [Abstract][Full Text] [Related]
20. Novel Prognostic Stratification Factor Based on the Pathological Profile of the Invasive Front in Colorectal Cancer.
Matsui H; Homma S; Hatanaka KC; Sawada A; Imaizumi K; Yoshida T; Ichikawa N; Emoto S; Miyaoka Y; Takahashi N; Matsuno Y; Hatanaka Y; Taketomi A
Anticancer Res; 2021 Jul; 41(7):3429-3438. PubMed ID: 34230138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
